Current Activities in Protein Engineering
This is a modal window.
The media could not be loaded, either because the server or network failed or because the format is not supported.
Formal Metadata
Title |
| |
Title of Series | ||
Number of Parts | 340 | |
Author | ||
License | CC Attribution - NonCommercial - NoDerivatives 4.0 International: You are free to use, copy, distribute and transmit the work or content in unchanged form for any legal and non-commercial purpose as long as the work is attributed to the author in the manner specified by the author or licensor. | |
Identifiers | 10.5446/55115 (DOI) | |
Publisher | ||
Release Date | ||
Language |
Content Metadata
Subject Area | ||
Genre | ||
Abstract |
|
00:00
PressureNobeliumMeeting/Interview
01:19
Rekombinante DNSProteinWursthülleMeeting/Interview
01:47
Rekombinante DNSSecretionProteinMeeting/Interview
02:16
Lamb and muttonMagmaDNAProteinSynthetic oilWater purificationMeeting/Interview
02:45
ValineHigh-performance liquid chromatographyIonenaustauschAageBiotechnologyMeeting/Interview
03:14
Columbia RecordsMaterials scienceErdölraffinationWursthülleSynthetic oilMeeting/Interview
03:42
LigandSetzen <Verfahrenstechnik>WalkingMixtureMaterials scienceSynthetic oilErdölraffinationMeeting/Interview
04:11
Water purificationProteinPeptideMeeting/Interview
04:40
BiosynthesisAmino acidSurface finishingMeeting/Interview
05:09
HydrocarboxylierungOligomereAmineMethoxygruppeBiomolecular structureMeeting/Interview
05:37
TryptophanPeptide synthesisPeptideBiosynthesisOligomereMeeting/Interview
06:06
PeptideMeeting/Interview
06:35
MachinabilityBiosynthesisOrganische ChemieProteinMeeting/Interview
07:03
Separation processProteinSystemic therapyMeeting/Interview
07:32
ProteinNucleaseMeeting/Interview
08:01
ThiolgruppeLysineDisulfideTryptophanSetzen <Verfahrenstechnik>Meeting/Interview
08:30
ErdrutschNucleaseMoleculeProteinfaltungMeeting/Interview
08:58
Chemical structureChain (unit)Meeting/Interview
09:27
Helicität <Chemie>ErdrutschC-terminusBeta sheetMeeting/Interview
09:56
TrypsinMoleculeCalciumMeeting/Interview
10:24
Conformational isomerismTrypsinLysineThymidinIonenbindungMeeting/Interview
10:53
HydroglimmerLysineElectronic cigaretteChemical structureMeeting/Interview
11:22
IonenbindungProteinChemical structurePeptideMeeting/Interview
11:51
WaterGlycerinTrypsinCalciumChemical reactionThiamindiphosphatBiosynthesisMeeting/Interview
12:19
Systemic therapyIonenbindungMoleculeActivity (UML)Meeting/Interview
12:48
Synthetic oilErdrutschDerivative (chemistry)ChemistryTrypsinPosttranslational modificationMeeting/Interview
13:17
Table wineHydroxybuttersäure <gamma->Activity (UML)Residue (chemistry)IonenbindungAmino acidCalciumSubstitutionsreaktionAtomMeeting/Interview
13:45
CarboxylierungCalciumCarboxylateActivity (UML)Glutamic acidProteinAspartic acidMeeting/Interview
14:14
ArginineResidue (chemistry)Multiprotein complexActivity (UML)PhosphateMoleculeChain (unit)Meeting/Interview
14:43
DNAErdrutschChemistryMutageneseMeeting/Interview
15:12
GenotypeNucleaseActivity (UML)Amino acidMutageneseMoleculeMeeting/Interview
15:40
ProteinAnomalie <Medizin>MoleculeMeeting/Interview
16:09
Data conversionSetzen <Verfahrenstechnik>Functional groupDisulfidbrückeWine tasting descriptorsMeeting/Interview
16:38
Chemical structureProteinArginineResidue (chemistry)Amino acidMeeting/Interview
17:07
Spawn (biology)Radioactive decayMan pageFluorescenceMeeting/Interview
17:35
MoleculeBoyle-Mariotte-GesetzAmino acidTryptophanMeeting/Interview
18:04
ProteinChemistryMeeting/Interview
18:33
TryptophanBreed standardConformational isomerismPhenylalanineMeeting/Interview
19:01
ArginineResidue (chemistry)PeptideChain (unit)CitronensäureLysineMeeting/Interview
19:30
MoleculeActivity (UML)TrypsinMeeting/Interview
19:59
PressureAmino acidElektronentransferTryptophanFluorescenceC-terminusMeeting/Interview
20:28
PeptideMeeting/Interview
20:56
PeptideDNAProteinMeeting/Interview
21:25
BiosynthesisPeptideMeeting/Interview
21:54
TrypsinCaffeineCarboxypeptidase BHigh-performance liquid chromatographyMeeting/Interview
22:22
C-terminusFunctional groupAreaEnzymeMeeting/Interview
22:51
Ene reactionSynthetic oilImpfung <Chemie>ProteinChemical structureMeeting/Interview
23:20
Helicität <Chemie>NucleolusMoleculeAreaProteinBeta sheetAlpha particleMeeting/Interview
23:49
BromcyanSolutionChemical structureSpaltflächeResidue (chemistry)Meeting/Interview
24:17
Antibodies (film)MoleculeMeeting/Interview
24:46
PressureNucleaseChemical structureNucleolusThermoformingMeeting/Interview
25:15
Injection (medicine)AntigenAntibodies (film)MixtureNucleaseMeeting/Interview
25:43
Columbia RecordsSphäroproteineAntibodies (film)Surface scienceNucleaseSystemic therapyActive siteMeeting/Interview
26:12
Antibodies (film)PeptideMeeting/Interview
26:41
PeptideMeeting/Interview
27:10
Binding energyAntibodyProteinAntibodies (film)NucleaseActivity (UML)Meeting/Interview
27:38
NucleaseProteinThermoformingActivity (UML)Chemical structureMeeting/Interview
28:07
Binding energyAntibodies (film)Impfung <Chemie>Synthetic oilMeeting/Interview
28:36
LysozymePeptide sequenceMixtureFreies ElektronImpfung <Chemie>Synthetic oilAntibodies (film)AageMeeting/Interview
29:05
ProteinOligomereImpfung <Chemie>Meeting/Interview
29:33
Impfung <Chemie>Neutralization (chemistry)Meeting/Interview
30:02
River mouthChemical structureAntibodies (film)Meeting/Interview
30:31
NobeliumStuffingImpfung <Chemie>PeptideLactitolMeeting/Interview
Transcript: English(auto-generated)
00:17
Thank you, parents, for your kind introduction.
00:22
I thought in this lecture that I would take the opportunity to show you all that, in spite of people winning Nobel Prizes and so on, that they can still dress in a more or less civilized way, so I've worn a tie and jacket.
00:42
So, I should also mention that I've changed the title of my speech, and for the next half hour I intend to discuss matters of nuclear power, human rights, nuclear weapons, and the like.
01:07
I really think they'd rather have this, you know. Okay. What I will talk to you about is not so much a large amount of detailed information, although I will make illustrations, of course, from our own work and from other people's work,
01:25
but a feeling that I personally and many other people also have about the directions in which the preparation of proteins will go. The development of the DNA recombinant methodology, of course, has made it
01:44
possible in many cases to prepare large molecules, proteins, hormones, et cetera, and this is now a tremendous industry throughout the world and very successful. At the same time, while this DNA recombinant methodology has improved so enormously, there has been, in a sort of quiet, secret way,
02:09
a great deal of improvement in the methodology of protein chemistry, particularly in the biosynthesis, in the organic synthesis of peptides, even quite large ones.
02:21
And I really feel that over the coming years, many of the proteins that are now being made or are being tried or are being attempted by DNA technology may be ultimately made by protein synthetic methods.
02:42
The technology, for example, of purification has improved enormously. The HPLC, the high performance liquid chromatography techniques, are not only much more specific and discerning than the old ion exchange methods and so on,
03:01
but they can be made on a very large scale. I was just visiting the biotechnology offshoot of the Carlsberg Laboratory in Copenhagen last week, and I'm impressed with the way that the large HPLC technology has come out from Millipore Waters in Boston
03:25
and is now present in many industrial and university laboratories, large enough to prepare, to take kilos in single runs, kilos of synthetic materials for purification, with great success.
03:40
And, of course, we have my own baby, which is affinity chromatography, which has also improved to a point where in many cases one can take a crude mixture of biological material or of synthetic material, pass it through an affinity column, that is to say an immobilized ligand column, which would catch only one type of substance,
04:06
and go very often from a great mixture of materials to a single component in one step. So between these methods we have now excellent purification techniques for proteins and polypeptides. The most important, of course, is the development of the synthetic methodology itself.
04:28
We have all been using the Merrifield solid phase method mostly, in spite of the fact that I think the purest, I think the purest large polypeptide that's been made synthetically was made entirely by hand, that is to say, not machines.
04:45
I'm thinking of Wunsch, who made glucagon, which is 50 amino acids. It took about three years, of course, and he had 27 graduate students crystallizing and so on, but it was very pure when it was finished. But that's too much trouble.
05:02
So the new methodology improves solid phase synthesis in the following way. Instead of using the most common protecting group, which is TBOC, tertiary butyloxy carbonyl group, for each for the monomer, and which has to be removed at each step with acid,
05:23
the newest likely monomer will be the so-called FMOC amino acids, 9-fluoronyl methoxy carbonyl, which can be removed with alkali, and this means a much more gentle, stepwise addition of monomeric units,
05:46
and also it has the advantage of permitting the synthesis of peptides containing tryptophan, because tryptophan is unstable to acid. With FMOC, one can make tryptophan peptides and have no problem.
06:01
So I do believe that without further complication, one could at the moment look forward to the synthesis of polypeptides of certainly 50 amino acids, I think, in length, and possibly 100 or so, by purely synthetic and completely automatic methods.
06:21
I know both the Applied Biosystems Laboratory in California and Milypore Waters in Boston are at the moment about to release to the public, for large amounts of money, machines that will use FMOC and allow the synthesis of fairly large peptides.
06:46
Well, I'd like to suggest another extension of proteins and biosynthesis, protein and organic synthesis, which suggests that we might be able to get even larger fragments.
07:04
We have been working with a technology which could be called stitching. By stitching, I mean sewing together two large pieces. It was developed originally by Laskowski and Holmberg in New York somewhere, Buffalo, I think.
07:22
And we've used it in our own laboratory with several protein systems with considerable success. It's a very, very interesting situation. I'd like to show you what I have in mind. I might just show you first the protein that we began in studying,
07:42
which is a protein called staphylococcal nuclease, a nuclease produced by Staph aureus as an extracellular protein from cultures. And I believe the first word is this thing. Here we have staphylococcal nuclease, 149 amino acids,
08:06
one tryptophan here. I should point out a lysine, lysine at 48, 49, and another one up here at 5, 6.
08:24
It has no disulfide bonds, so there are no problems with SS formation from thiol groups. And the molecule, if denatured completely and allowed to renature,
08:41
folds up in three dimensions with a half time of about 200 milliseconds, very rapid folding. The next slide shows the staph nuclease molecule in a simple folded up diagram
09:06
taken from the crystallographic work on the three-dimensional structure. This three-dimensional structure was worked out by Dr. Cotton and his colleagues at MIT some years ago. And you will see here a chain which suddenly becomes an anti-parallel pleated sheet
09:27
and helix, another anti-parallel pleated sheet, and two more helices closer to the carboxyl terminus. And perhaps one more slide using a notation developed by Jane Richardson at Duke
09:46
which is convenient, showing the helices as little twisted bundles and these anti-parallel pleated sheets as arrows.
10:00
Now, if you attack this molecule with trypsin which, of course, splits between lysine and arginine, it splits following lysine and arginine. And if you protect the rest of the molecule by adding calcium in here and thymidine diphosphate,
10:27
three prime, five prime, thymidine diphosphate, the ligands, the two ligands, protect the rest of the molecule and keep it in a tight conformation. But you can see here, sticking out into the solution,
10:44
a loop which contains lysine, lysine, 48, 49 that I showed you before. When trypsin is added to this, you cleave that lysine, lysine bond and also this 5, 6 lysine, lysine up at the end
11:01
and you get two pieces, one fragment from 6 to 49 and one from 50 to 149. The two pieces separately, the large piece and the small piece, have no structure of their own but if you mix them together, in spite of this cleavage,
11:24
they combine, they form a folded structure which is completely isomorphous with the native molecule so that the same structure is achieved without that bond. Now the important thing that I want to make, the important point I want to make now is that
11:44
if one could make large peptide fragments synthetically, it's possible to stitch them together and regenerate the original protein. In this particular case, if you take these two pieces in the presence of calcium and thiamine diphosphate
12:02
and add trypsin, but now not in water but in 90% glycerol, if you decrease the water in the solution and increase the glycerol concentration, the equilibrium of the trypsin reaction is shifted towards synthesis instead of cleanage
12:21
and this bond can be reformed almost in 100% yield, goes to completion and you regenerate the molecule in quite good yield and activity. So we have then the possibility of making something quite large by taking advantage of this stitching technique.
12:47
I'll show you in a moment, we're trying it on another system now. Using such, the next slide perhaps, here we have another photograph of this trypsin cleavage,
13:00
giving this small piece and this large piece. Now as a study in chemical modification by synthetic methods, we proceeded to make quite a large number of derivatives of this smaller fragment
13:20
which is 43 amino acids and could replace many of the residues here with substitutions that still permitted full activity when this bond was made.
13:42
For example, around this calcium, this calcium atom which is required for activity, is liganded by four carboxyl groups, which is a standard situation with calcium. We found that the substitution of any one of those four carboxyl groups
14:03
by transforming glutamic acid to glutamine or aspartic acid to asparagine destroyed the ability to reform the protein and the activity was gone. The polynucleotide chain runs up through this groove in the molecule
14:22
and there is an arginine residue ordinarily here in the chain which complexes with a phosphate group. If this arginine is replaced by a citrulline, once again the activity is destroyed. So we found a number of changes that were permitted and a number that were not permitted.
14:44
So, in a sense, these are what you might call chemical site-directed mutagenesis not involving DNA. On the other hand, of course, the DNA technology is so powerful that at the moment
15:01
this kind of thing can be done much more quickly and I borrowed a slide from Dr. David Shortle at Johns Hopkins which shows what sort of success he has had. Here is the same staphylococcal nuclease molecule. These X's along here represent mutations that he and his colleagues have introduced by random mutagenesis
15:30
and then insertion into E. coli which would express each one of these separately. They developed a technique for picking out active and inactive single amino acid mutants.
15:46
And he has, I think, out of 149 amino acids, he has something like 94 different varieties. It is a very powerful technique. We have recently begun to study another protein using the same methodology
16:02
and I should tell you why. This is a molecule known as thioredoxin. It is a very common molecule in nature, particularly in large amounts in a number of bacteria, salmonella, E. coli, etc.
16:20
It is involved in catalyzing disulfide bond formation in the maturation of bacteriophage, the conversion of ribonucleotides to deoxyribonucleotides. It has a number of different functions. But for us in particular, it is a nice protein to work with because it is quite small, you see.
16:43
It is only 109 amino acids. And its structure has been worked out quite accurately by Bundin in Sweden. It has a single arginine residue here.
17:02
What we have been doing, and I should mention first of all why thioredoxin. Down the hall from me in Hopkins is a man called Dr. Ludwig Brand, who is, I think, quite well known in the field of fluorescence. And he has extremely fine equipment now with laser fluorescence
17:23
and the proper computer technology for fishing out the four or five decay half-times and so on and so forth. So what we are starting to do now is to take this molecule,
17:41
which contains two tryptophanes, one tryptophane here, one tryptophane here, which of course are the ideal amino acid for people interested in fluoroscopy. And he has so far been doing studies on the native molecule
18:03
to get some idea of the half-life decay times for these tryptophanes. Now, since it is a university and we have students who have to learn as much as they can, it is a great opportunity to combine some protein chemistry and some genetics.
18:24
So in my laboratory at the moment, three students are working on the site-directed immunogenesis of this protein, using the standard cDNA plasmids, lambda, phage, vector, etc.,
18:43
which I do not know much about but I am learning. They have made one mutant containing phenylalanine replacing tryptophane here and another one with phenylalanine here. And Lenny Brannan assures me that by studying these he can learn a great deal about the conformation in that region.
19:08
I, on the other hand, am anxious to expose these students to some organic chemistry, some peptide chemistry, so what we have done is to block all of the lysine residues along the chain
19:22
with citric corneal groups, which can be added very easily, leaving only the arginine residue as the residue sensitive to trypsin. The molecule can then be treated with trypsin and split so that we get this piece and this large piece.
19:44
Then the citric corneal can be taken off very easily. The two pieces can be added together. They have some activity without being joined, but at this particular moment we have synthesized this fragment using TBOC,
20:04
and we are going to repeat it now using FMOC in the native form, and also have begun some studies on the introduction of various fluorescent amino acids in place of some of these C-terminal ones that are sticking out here,
20:22
hoping to be able to get not only additional fluorescent centers, but also centers for energy, the study of energy transfer between the tryptophanes here and something in the C-terminus. So as a teaching situation, it's quite nice. I think that whether they like it or not, they have to stop making mutants and synthesize the peptide.
20:48
So it's a good training situation. Well, all in all, let me just finish this business. I really think that with this stitching technique and a little careful designing,
21:02
and with the improved synthetic technology, that we really should be able to make proteins certainly this size, I think, one way or another in the next two years. I think this can be developed. It will never equal the DNA technology for very large proteins, of course. But I think in terms of medically important substances,
21:24
the many, many, many peptides that are now being used and discovered in medicine, that synthesis will become the important one. I mentioned Copenhagen before. I visited this Carlsberg Biotech Company last week, which is entirely devoted to this kind of thing.
21:50
They are concentrating entirely on organic synthesis and have a number of peptides that they have made in rather large quantities
22:01
and very clean because of this large-scale HPLC method. They are using not just trypsin and carboxypeptidase and a few other things, but they are using a whole variety of enzymes, including caffeine and other pancreatic proteins, calmatrypsin and so on,
22:24
and arranging the C-terminus of the portion to which the smaller piece should be added with different blocking groups that are more specific for the enzyme in question. I think they are doing quite well and are starting to sell some clean things that went through the FDA.
22:46
Finally, I'd like to say a word about another area that I really think will become very important in medical science, in industrial medical science for that matter, and that is the whole idea of vaccines, synthetic vaccines.
23:14
One is interested in whether or not small pieces of proteins can fold into the three-dimensional structure
23:23
that's characteristic of that piece when it's part of the protein molecule. For example, with staph nuclei is the one I showed you before. You have this pleated sheet area and three alpha helical portions.
23:41
You can chop the molecule in different ways. The one I'll mention now specifically is the smallest piece, it's 99 to 149, which is prepared with cyanogen bromide cleavage of a methionine residue.
24:02
You ask yourself, will such a piece, in solution by itself, take on some three-dimensional structure that resembles what it used to have when it was part of the protein? Now, putting it in immunological terms, if this is an antigenic determinant,
24:23
if you make antibodies against nuclease, and this happens to be one of the determinants against which an antibody is made, can you use such a little piece as a competitor or a recognition molecule for the antibody?
24:44
Will it remember what it used to look like? So, what we have done with staph nuclei is to simply begin on this kind of, studying this question, is to look at this C-terminal portion running from 99 to 149.
25:04
This would be the random form without structure. And we ask the question, is this piece of nuclease in equilibrium with a structure that resembles the native conformation?
25:21
If this were an antigenic determinant in the native molecule, then this piece would be recognized by the proper antibody. So, to test that, we made antibodies against native nuclease by injection into rabbits,
25:42
and produced, of course, a great mixture of anti-nuclease antibodies, one antibody against each antigenic site on the surface of the globular protein. To clean up the system a little bit, we attached,
26:01
we took sepharose and attached to it some nuclease and caught the total antibody population on that column of nuclease sepharose. Then that peak, which was eluted with acid,
26:21
was then passed through another column to which had been attached the peptide 99 to 149, and of this whole large population of antibodies, a much smaller population was caught, namely anti-99 to 149. However, this antibody preparation here turned out to be polyvalent.
26:47
That is to say, if we added this to nuclease, we got a precipitate, so it had more than one antigenic site. So, we simply took this peak, put it through still another column,
27:01
containing only 99 to 126, the peptide attached to the column, and then we got out this one. I'm sorry. We attached to the column 127 to 149 and caught the antibody that we did not want and got anti-99 to 126, which is a non-precipitating antibody.
27:26
It does, however, inhibit, it binds to the protein and inhibits the activity, destroys the activity. So we had then a specific antibody that would bind and inactivate nuclease.
27:43
By doing some kinetic measurements on the activity of nuclease against DNA, its substrate, with increasing the amounts of anti-99 to 126, we could calculate that that piece, that piece of protein 99 to 126,
28:04
existed in a form sufficiently similar to the native structure to bind to the antibody about 1% of the time. It's not a lot, but at least about 1% of the time it looked like it should,
28:21
and that's good enough for this kind of synthetic vaccine work that I want to mention. And then we've done this with other bits of proteins, and it turns out that you can't isolate a single determinant, which can be used for the purpose of vaccine preparation.
28:43
This was an old experiment with lysozyme many years ago, where we took the loop, there's a loop of amino acid sequence that sticks out from lysozyme, which could be synthesized and attached to a large carrier molecule, injected into rabbits,
29:02
and that synthetic mixture produced an antibody that would inactivate lysozyme. So it was like a vaccine against lysozyme, essentially. More reasonably is this situation, which was work done by Ruth Arnone and her colleagues at the Weissmann Institute,
29:24
where the coat protein of MS2 virus, it's a coliphase, this is the monomer of the coat protein, could be broken up into three pieces, turned out that this second piece was the antigenically active piece,
29:41
and this could be synthesized, attached to a carrier, and could neutralize MS2 virus like any normal vaccine. This principle, I think, is being used now quite widely. I know it, certainly, at the Scripps Institute in California,
30:03
at the Weissmann Institute, and a number of other places, people are looking into making pieces of coat proteins, it's mostly viral coat proteins, that are large enough to form a bit of structure that's recognized by the antibody against the total virus.
30:24
I know that work is actively going on with hoof and mouth disease, influenza, cholera, and a few other things, and it's based entirely on this idea of the ability of small peptides to remember what they once looked like,
30:43
and I think it may become an important aspect of vaccine production. So perhaps I won't talk about nuclear weapons and human rights after all of this stuff.